PURI.L Share News (PURI)

Gene therapies developer Oxford Biomedica is higher following an R&D presentation for investors. It is also part of a collaborative research project that will receive a £255,000 grant from the UK Motor Neurone Disease Association for the further evaluation of MoNuDin® for the treatment of amyotrophic lateral sclerosis. ProStrakan shares have perked up after its partner Endo Pharmaceuticals submitted a response to the FDA letter concerning FORTESTA? (testosterone) 2% Gel. Endo intends to sell this in the US for men diagnosed with low testosterone, also known as hypogonadism. Endo has reaffirmed the reliability of its study results. It could take six months for the FDA to reply. Shares in water-based cleaning technology provider Puricore are heading lower the day before ten existing shares are consolidated into one new share. FTSE TechMARK - RisersTorotrak (TRK) 19.75p +3.80%Oxford Biomedica (OXB) 11.25p +2.27%Consort Medical (CSRT) 385.00p +1.18%ProStrakan (PSK) 68.00p +1.12%ARM Holdings (ARM) 280.40p +1.05%Emblaze (BLZ) 31.50p +0.80%Aveva Group (AVV) 1,138.00p +0.71%Cable & Wireless Worldwide (CW.) 87.20p +0.69%Oxford Instruments (OXIG) 281.25p +0.45%FTSE TechMARK - FallersRM Group (RM.) 180.25p -7.56%Puricore (PURI) 7.38p -6.35%Antisoma (ASM) 5.50p -5.17%Phoenix IT Group (PNX) 236.25p -4.64%NXT (NTX) 11.25p -4.44%Innovation Group (TIG) 11.25p -4.26%Renovo Group (RNVO) 27.00p -3.57%Ricardo Group (RCDO) 265.25p -3.37%XP Power (XPP) 560.50p -3.36%Parity Group (PTY) 8.50p -2.94%